SCHEMBL13724554

SCHEMBL13724554

CNC(=O)C1CCCN(c2ccc(N)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.52
JAK1 P23458 1/20 0.52
JAK3 P52333 1/20 0.52
NOTUM Q6P988 2/20 0.49
RXFP1 Q9HBX9 1/20 0.47
DEGS1 O15121 1/20 0.46
MAP4K4 O95819 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 2/20 0.44
MAPT P10636 2/20 0.44
CASP6 P55212 1/20 0.43
GFER P55789 1/20 0.43
TSHR P16473 3/20 0.43
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 3/20 0.42
GAA P10253 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15653408 1.00 SYK (0.52) SYKJAK1JAK3NOTUMRXFP1
SCHEMBL13733384 0.92 NOTUM (0.57) SYKJAK1JAK3NOTUMRXFP1
SCHEMBL16994779 0.87 TSHR (0.53) SYKJAK1JAK3NOTUMRXFP1
SCHEMBL4490863 0.84 SYK (0.48) SYKJAK1JAK3NOTUMRXFP1
SCHEMBL14711365 0.83 MAPT (0.47) NOTUMDEGS1ALDH1A1MAPK1MAPT
SCHEMBL14712094 0.83 MAPT (0.47) NOTUMDEGS1ALDH1A1MAPK1MAPT
SCHEMBL13724599 0.82 GFER (0.51) SYKNOTUMRXFP1MAP4K4ALDH1A1
SCHEMBL79756 0.82 WDR91 (0.52) SYKJAK1JAK3NOTUMALDH1A1
SCHEMBL14320629 0.81 ALDH1A1 (0.52) SYKJAK3NOTUMALDH1A1MAPK1
SCHEMBL12006548 0.77 ALDH1A1 (0.71) ALDH1A1MAPK1MAPTKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
EP-2699572-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Origenis GmbH (DE) 2014-02-26 EP disclosed
EP-2699579-A1 PYRAZOLO [4, 3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS Origenis GmbH (DE) 2014-02-26 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed
WO-2012143144-A1 PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 WO disclosed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK SYK 11/4885JAK1 100/4885JAK3 219/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK SYK 9/4885JAK1 55/4885JAK3 80/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK SYK 11/4885JAK1 100/4885JAK3 219/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK SYK 11/4885JAK1 100/4885JAK3 219/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 SYK 7/4885JAK1 158/4885JAK3 335/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK SYK 9/4885JAK1 70/4885JAK3 144/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK SYK 9/4885JAK1 70/4885JAK3 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.